GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calidi Biotherapeutics Inc (AMEX:CLDI) » Definitions » Other Operating Expense

CLDI (Calidi Biotherapeutics) Other Operating Expense : $-0.18 Mil (TTM As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Calidi Biotherapeutics Other Operating Expense?

Calidi Biotherapeutics's Other Operating Expense for the three months ended in Dec. 2024 was $0.00 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2024 was $-0.18 Mil.

Calidi Biotherapeutics's quarterly Other Operating Expense increased from Jun. 2024 ($-0.18 Mil) to Sep. 2024 ($0.00 Mil) but then stayed the same from Sep. 2024 ($0.00 Mil) to Dec. 2024 ($0.00 Mil).

Calidi Biotherapeutics's annual Other Operating Expense declined from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($-2.89 Mil) but then increased from Dec. 2023 ($-2.89 Mil) to Dec. 2024 ($-0.18 Mil).

Calidi Biotherapeutics Other Operating Expense Historical Data

The historical data trend for Calidi Biotherapeutics's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Calidi Biotherapeutics Other Operating Expense Chart

Calidi Biotherapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Other Operating Expense
- - - -2.89 -0.18

Calidi Biotherapeutics Quarterly Data
Dec20 Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.61 - -0.18 - -

Calidi Biotherapeutics Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.18 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Calidi Biotherapeutics Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Calidi Biotherapeutics's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Calidi Biotherapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calidi Biotherapeutics Inc (AMEX:CLDI) » Definitions » Other Operating Expense
Comparable Companies
INAB AFMD ABVC PHGE BIVI EQ MBRX BOLT ZEOX SABS VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
4475 Executive Drive, Suite 200, San Diego, CA, USA, 92121
Website
https://www.calidibio.com
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.